Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Sponsor: Neurocrine Biosciences
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-12-24
Completion Date
2028-02
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
NBI-1117568
Oral administration
Placebo
Oral administration
Locations (6)
Neurocrine Clinical Site
Garden Grove, California, United States
Neurocrine Clinical Site
Hollywood, California, United States
Neurocrine Clinical Site
San Diego, California, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Gaithersburg, Maryland, United States
Neurocrine Clinical Site
Marlton, New Jersey, United States